Tissue distribution and metabolism of the putative cancer chemopreventive agent 3′,4′,5′-trimethoxyflavonol (TMFol) in mice

Biomedical Chromatography

Volumn 26, Issue 12, 2012, Pages 1559-1566

  Saad, Shaban E A ^a   Jones, Donald J L ^a   Norris, Leonie M ^a   Horner Glister, Emma ^a   Patel, Ketan R ^a   Britton, Robert G ^a   Steward, William P ^a   Gescher, Andreas J ^a   Brown, Karen ^a   Sale, Stewart ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

3 , 4 , 5 trimethoxyflavonol; Colorectal cancer chemoprevention; High performance liquid chromatography; Prostate cancer chemoprevention

Indexed keywords

BIOMOLECULES; DISEASES; HISTOLOGY; MAMMALS; METABOLITES; TISSUE; UROLOGY;

3′, 4′, 5′-TRIMETHOXYFLAVONOL; CANCER CHEMOPREVENTION; CHEMOPREVENTIVE; COLORECTAL CANCER CHEMOPREVENTION; GASTROINTESTINAL TRACT; HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY; PROSTATE CANCER CHEMOPREVENTION; PROSTATE CANCERS; TIME POINTS;

HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

3',4',5' TRIMETHOXYFLAVONOL; FLAVONOL DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; GASTROINTESTINAL TRACT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PROSTATE; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TISSUE DISTRIBUTION;

MUS;

EID: 84867739045     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.2732     Document Type: Article

References (19)

1. Ader P, Wessmann A and Wolffram S. Bioavailability and metabolism of the flavonol quercetin in the pig. Free Radical Biology & Medicine 2000; 28: 1056-1067.
2. Asea A, Ara G, Teicher BA, Stevenson MA and Calderwood SK. Effects of the flavonoid drug quercetin on the response of human prostate tumours to hyperthermia in vitro and in vivo. International Journal of Hyperthermia 2001; 17: 347-356.
3. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry 1976; 72: 248-254.
4. Britton RG, Fong I, Saad S, Brown K, Steward WP, Gescher A and Sale S. Synthesis of the flavonoid 3′, 4′, 5′-trimethoxyflavonol and its determination in plasma and tissues of mice by HPLC with fluorescence detection. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 2009; 877: 939-942.
5. Dunnick JK and Hailey JR. Toxicity and carcinogenicity studies of quercetin, a natural component of foods. Fundamental and Applied Toxicology 1992; 19: 423-431.
6. Ferry DR, Smith A, Malkhandi J, Fyfe DW, deTakats PG, Anderson D, Baker J and Kerr DJ. Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clinical Cancer Research 1996; 2: 659-668.
7. Fiorani M, Accorsi A and Cantoni O. Human red blood cells as a natural flavonoid reservoir. Free Radical Research 2003; 37: 1331-1338.
8. Howells L, Britton RG, Mazzoletti M, Greaves P, Broggini M, Brown K, Steward WP, Gescher A and Sale S. Preclinical colorectal cancer chemopreventive efficacy and p53-modulating activity of 3′, 4′, 5′-trimethoxyflavonol, a quercetin analogue. Cancer Prevention Research (Philadelphia, Pa.) 2010; 3: 929-939.
9. Jones DJ, Lamb JH, Verschoyle RD, Howells LM, Butterworth M, Lim CK, Ferry D, Farmer PB and Gescher AJ. Characterisation of metabolites of the putative cancer chemopreventive agent quercetin and their effect on cyclo-oxygenase activity. Britsh Journal of Cancer 2004; 91: 1213-1219.
10. Khan N, Asim M, Afaq F, Abu Zaid M and Mukhtar H. A novel dietary flavonoid fisetin inhibits androgen receptor signaling and tumor growth in athymic nude mice. Cancer Research 2008; 68: 8555-8563.
11. Ma ZS, Huynh TH, Ng CP, Do PT, Nguyen TH and Huynh H. Reduction of CWR22 prostate tumor xenograft growth by combined tamoxifen-quercetin treatment is associated with inhibition of angiogenesis and cellular proliferation. International Journal of Oncology 2004; 24: 1297-1304.
12. MacGregor JT and Jurd L. Mutagenicity of plant flavonoids: structural requirements for mutagenic activity in Salmonella typhimurium. Mutation Research 1978; 54: 297-309.
13. Manach C, Texier O, Morand C, Crespy V, Régérat F, Demigné C and Rémésy C. Comparison of the bioavailability of quercetin and catechin in rats. Free Radical Biology & Medicine 1999; 27: 1259-1266.
14. Neuhouser ML. Dietary flavonoids and cancer risk: evidence from human population studies. Nutrition and Cancer 2004; 50: 1-7.
15. Reagan-Shaw S, Nihal M and Ahmad N. Dose translation from animal to human studies revisited. The FASEB Journal 2008 22: 659-661.
16. Saad S, Howells LM, Britton RG, Steward WP, Gescher A, Brown K and Sale S. 3′, 4′, 5′-Trimethoxyflavonol (TMFol), a novel putative prostate cancer chemopreventive agent: in vitro and in vivo preclinical activity. Cancer Prevention Research 2010; 3(12 suppl.): A104.
17. Shia CS, Tsai SY, Kuo SC, Hou YC and Chao PD. Metabolism and pharmacokinetics of 3, 3′, 4′, 7-tetrahydroxyflavone (fisetin), 5-hydroxyflavone, and 7-hydroxyflavone and antihemolysis effects of fisetin and its serum metabolites. Journal of Agricultural and Food Chemistry 2009; 57: 83-89.
18. Touil YS, Auzeil N, Boulinguez F, Saighi H, Regazzetti A, Scherman D and Chabot GG. Fisetin disposition and metabolism in mice: identification of geraldol as an active metabolite. Biochemical Pharmacology 2011; 82: 1731-1739.
19. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham DA, Glennie MJ, Kelland LR, Robinson V, Stratford IJ, Tozer GM, Watson S, Wedge SR and Eccles SA. Committee of the National Cancer Research Institute. Guidelines for the welfare and use of animals in cancer research. British Journal of Cancer 2010; 102: 1555-1577.